|
Volumn 37, Issue 5, 2011, Pages 1283-1285
|
Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: Is "blind" treatment dangerous?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMIKACIN;
CYCLOSERINE;
ETHAMBUTOL;
ETHIONAMIDE;
ISONIAZID;
KANAMYCIN;
OFLOXACIN;
PYRAZINAMIDE;
RIFAMPICIN;
STREPTOMYCIN;
BACTERIAL STRAIN;
BACTERIUM ISOLATE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG SAFETY;
GENE MUTATION;
GENOTYPE;
HUMAN;
LETTER;
LUNG TUBERCULOSIS;
MYCOBACTERIUM;
PHENOTYPE;
PRACTICE GUIDELINE;
PREDICTIVE VALUE;
PRIORITY JOURNAL;
SPUTUM;
ANTITUBERCULAR AGENTS;
BURKINA FASO;
CHRONIC DISEASE;
HIV INFECTIONS;
HUMANS;
MYCOBACTERIUM TUBERCULOSIS;
SPUTUM;
TREATMENT FAILURE;
TUBERCULOSIS, MULTIDRUG-RESISTANT;
TUBERCULOSIS, PULMONARY;
|
EID: 79955663749
PISSN: 09031936
EISSN: 13993003
Source Type: Journal
DOI: 10.1183/09031936.00144710 Document Type: Letter |
Times cited : (10)
|
References (12)
|